{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T22:05:34Z","timestamp":1784930734443,"version":"3.55.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.breast.2026.104830","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T23:28:42Z","timestamp":1780356522000},"page":"104830","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A mixed prebiotic\/probiotic intervention (MBR-01) for the management of diarrhea during abemaciclib treatment of early breast cancer in postmenopausal patients: A single-center prospective case\u2013control pilot study"],"prefix":"10.1016","volume":"88","author":[{"given":"Daniele","family":"Generali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9031-8698","authenticated-orcid":false,"given":"Alexandro","family":"Membrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Gattazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Strina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Milani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Cervoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5952-4333","authenticated-orcid":false,"given":"Aldo","family":"Caltavituro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8131-974X","authenticated-orcid":false,"given":"Andrea","family":"Castagnetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Del Bianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6561-1919","authenticated-orcid":false,"given":"Francesco","family":"Schettini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.breast.2026.104830_bib1","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.3390\/cancers13061458","article-title":"Endocrine-based treatments in clinically-relevant subgroups of hormone Receptor-Positive\/HER2-Negative metastatic breast cancer: systematic review and meta-analysis","volume":"13","author":"Schettini","year":"2021","journal-title":"Cancers"},{"issue":"10503","key":"10.1016\/j.breast.2026.104830_bib2","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0140-6736(25)01013-X","article-title":"Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy","volume":"406","author":"Braybrooke","year":"2025","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.breast.2026.104830_bib3","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S1470-2045(19)30804-6","article-title":"CDK4\/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US food and drug administration pooled analysis","volume":"21","author":"Gao","year":"2020","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.breast.2026.104830_bib4","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/jnci\/djaa071","article-title":"Overall survival of CDK4\/6-inhibitors-based treatments in clinically relevant subgroups of metastatic breast cancer: systematic review and meta-analysis","volume":"112","author":"Schettini","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.breast.2026.104830_bib5","doi-asserted-by":"crossref","first-page":"608","DOI":"10.3389\/fonc.2018.00608","article-title":"CDK 4\/6 inhibitors as single agent in advanced solid tumors","volume":"8","author":"Schettini","year":"2018","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104830_bib6","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","article-title":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Johnston","year":"2023","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.breast.2026.104830_bib7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.annonc.2025.10.005","article-title":"Overall survival with abemaciclib in early breast cancer","volume":"37","author":"Johnston","year":"2026","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.breast.2026.104830_bib8","doi-asserted-by":"crossref","DOI":"10.1002\/onco.13691","article-title":"Management of abemaciclib\u2010associated adverse events in patients with hormone receptor\u2010positive, human epidermal growth factor receptor 2\u2010Negative advanced breast cancer: safety analysis of MONARCH 2 and MONARCH 3","volume":"26","author":"Rugo","year":"2021","journal-title":"Oncologist"},{"issue":"34","key":"10.1016\/j.breast.2026.104830_bib9","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.20.02514","article-title":"Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE)","volume":"38","author":"Johnston","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104830_bib10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41523-024-00639-1","article-title":"Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study","volume":"10","author":"Goetz","year":"2024","journal-title":"npj Breast Cancer"},{"issue":"8","key":"10.1016\/j.breast.2026.104830_bib11","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.chembiol.2019.05.005","article-title":"Multi-omics profiling establishes the polypharmacology of FDA approved CDK4\/6 inhibitors and the potential for differential clinical activity","volume":"26","author":"Hafner","year":"2019","journal-title":"Cell Chem Biol"},{"issue":"2","key":"10.1016\/j.breast.2026.104830_bib12","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1158\/1541-7786.MCR-17-0468","article-title":"Competitive kinase enrichment proteomics reveals that abemaciclib inhibits GSK3\u03b2 and activates WNT signaling","volume":"16","author":"Cousins","year":"2018","journal-title":"Mol Cancer Res"},{"issue":"2","key":"10.1016\/j.breast.2026.104830_bib13","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1158\/1535-7163.MCT-18-0734","article-title":"Intestinal toxicity in rats following administration of CDK4\/6 inhibitors is independent of primary pharmacology","volume":"18","author":"Thibault","year":"2019","journal-title":"Mol Cancer Therapeut"},{"issue":"4","key":"10.1016\/j.breast.2026.104830_bib14","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1007\/s11010-024-05077-y","article-title":"Gut microbiota regulates gut homeostasis, mucosal immunity and influences immune-related diseases","volume":"480","author":"Ding","year":"2025","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.breast.2026.104830_bib15","article-title":"Dysbiosis of the gut microbiota in disease","volume":"26","author":"Carding","year":"2015","journal-title":"Microb Ecol Health Dis"},{"key":"10.1016\/j.breast.2026.104830_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102816","article-title":"Navigating the complex relationship between human gut microbiota and breast cancer: physiopathological, prognostic and therapeutic implications","volume":"130","author":"Schettini","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.breast.2026.104830_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.112948","article-title":"Faecal microbiota composition is related to response to CDK4\/6-inhibitors in metastatic breast cancer: a prospective cross-sectional exploratory study","volume":"191","author":"Schettini","year":"2023","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.breast.2026.104830_bib18","article-title":"113P dynamic changes in gut microbiota in patients with ER+\/HER2- breast cancer treated with cyclin-dependent kinase 4\/6 inhibitors","volume":"10","author":"Donato","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.breast.2026.104830_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2021.634897","article-title":"Modulation of gut microbiota and immune system by probiotics, pre-biotics, and post-biotics","volume":"8","author":"Liu","year":"2022","journal-title":"Front Nutr"},{"issue":"9","key":"10.1016\/j.breast.2026.104830_bib20","doi-asserted-by":"crossref","first-page":"e1113","DOI":"10.1093\/oncolo\/oyae101","article-title":"Optimizing abemaciclib-induced diarrhea management in patients with breast cancer: a pragmatic 2-group study using a postbiotic microbiota stabilizer","volume":"29","author":"De Sanctis","year":"2024","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.breast.2026.104830_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2019.100772","article-title":"Clostridium butyricum modulates the microbiome to protect intestinal barrier function in mice with antibiotic-induced dysbiosis","volume":"23","author":"Hagihara","year":"2019","journal-title":"iScience"},{"issue":"1","key":"10.1016\/j.breast.2026.104830_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-94572-z","article-title":"Clostridium butyricum enhances colonization resistance against Clostridioides difficile by metabolic and immune modulation","volume":"11","author":"Hagihara","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.breast.2026.104830_bib23","article-title":"Intestinal mucosal immunity-mediated modulation of the gut microbiome by oral delivery of Enterococcus faecium against salmonella enteritidis pathogenesis in a laying hen model","volume":"13","author":"Huang","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.breast.2026.104830_bib24","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/304149","article-title":"Enterococcus faecium NCIMB 10415 modulates epithelial integrity, heat shock protein, and proinflammatory cytokine response in intestinal cells","volume":"2015","author":"Klingspor","year":"2015","journal-title":"Mediat Inflamm"},{"issue":"4","key":"10.1016\/j.breast.2026.104830_bib25","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.clnu.2013.10.002","article-title":"Probiotic supplementation for respiratory and gastrointestinal illness symptoms in healthy physically active individuals","volume":"33","author":"West","year":"2014","journal-title":"Clin Nutr"},{"issue":"8","key":"10.1016\/j.breast.2026.104830_bib26","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nrgastro.2017.75","article-title":"Expert consensus document: the international scientific association for probiotics and prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics","volume":"14","author":"Gibson","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.breast.2026.104830_bib27","unstructured":"Using a mixed probiotic\/prebiotic supplement (MBR-01) to help prevent diarrhea in patients taking abemaciclib for early breast cancer [Internet]. ISRCTN Registry. [cited December 11, 2025]. Available at: https:\/\/www.isrctn.com\/ISRCTN11948182."},{"issue":"4","key":"10.1016\/j.breast.2026.104830_bib28","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/ismej.2016.176","article-title":"Faecalibacterium prausnitzii: from microbiology to diagnostics and prognostics","volume":"11","author":"Lopez-Siles","year":"2017","journal-title":"ISME J"},{"key":"10.1016\/j.breast.2026.104830_bib29","doi-asserted-by":"crossref","unstructured":"Lenoir M, Mart\u00edn R, Torres-Maravilla E, Chadi S, Gonz\u00e1lez-D\u00e1vila P, Sokol H, et al. Butyrate mediates anti-inflammatory effects of Faecalibacterium prausnitzii in intestinal epithelial cells through Dact3. Gut Microbes. 12(1):1\u201316..","DOI":"10.1080\/19490976.2020.1826748"},{"key":"10.1016\/j.breast.2026.104830_bib30","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.3389\/fimmu.2018.02318","article-title":"Commensal Escherichia coli strains can promote intestinal inflammation via differential Interleukin-6 production","volume":"9","author":"Kittana","year":"2018","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.breast.2026.104830_bib31","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.3390\/jcm14113673","article-title":"A review of the influence of prebiotics, probiotics, synbiotics, and postbiotics on the human gut microbiome and intestinal integrity","volume":"14","author":"Smolinska","year":"2025","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.breast.2026.104830_bib32","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3892\/ijo.2024.5632","article-title":"Butyrate as a promising therapeutic target in cancer: from pathogenesis to clinic","volume":"64","author":"Sun","year":"2024","journal-title":"Int J Oncol"},{"key":"10.1016\/j.breast.2026.104830_bib33","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.breast.2023.07.003","article-title":"Efficacy of probiotics and trimebutine maleate for abemaciclib-induced diarrhea: a randomized, open-label phase II trial (MERMAID, WJOG11318B)","volume":"71","author":"Masuda","year":"2023","journal-title":"Breast"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626001402?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626001402?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T21:29:45Z","timestamp":1784928585000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626001402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":33,"alternative-id":["S0960977626001402"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104830","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A mixed prebiotic\/probiotic intervention (MBR-01) for the management of diarrhea during abemaciclib treatment of early breast cancer in postmenopausal patients: A single-center prospective case\u2013control pilot study","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104830","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104830"}}